Concurrent Immunotherapy With Stereotactic Radiation for Brain Metastases is Not Associated With Increased Rates of Radionecrosis

CONCLUSION: In this large single-institution study of linear accelerator-based SRT, consistent with previous reports, we found that lesion diameter positively correlated with risk of RN. However, there was not an increased risk of RN in patients who received ICI. On subset analysis, there was no association of RN with ICI timing - including with concurrent administration. These data suggest that linear accelerator-based SRT is safe to combine with ICI.AUTHOR DISCLOSURE: S.G. Allen: Employee; University of Michigan Mott Children's Hospital. J.J. Waninger: None. S.R. Birer: None. S. Journey: None. J. Skvarce: None. D.R. Wahl: Research Grant; Agios Inc, Innocrin Inc, American Cancer Society, NIH. Stock Options; Lycera Inc. Advisory Board Member; Agios Inc. T.S. Lawrence: None. J.A. Hayman: Research Grant; Blue Cross Blue Shield of Michigan. M.M. Kim: Research Grant; Blue Earth Diagnostics.; Red Journal. Site PI of ongoing CCTG CE.7, N0577, A071801, and NCI 9979 trials; NCTN (Alliance, NRG, CCTG) and ETCTN.M. Green: None.PMID:34701756 | DOI:10.1016/j.ijrobp.2021.07.1522
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research